Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9576486 | 0.79 | SMN1; SMN2 (0.46) | GAAL3MBTL1TDP1MAPTGDA | |
| SCHEMBL19018643 | 0.79 | GAA (0.51) | GAAL3MBTL1TDP1MAPTGDA | |
| SCHEMBL13176680 | 0.75 | — | — | |
| SCHEMBL3258892 | 0.74 | GDA (0.43) | GAAL3MBTL1TDP1MAPTGDA | |
| SCHEMBL1560676 | 0.74 | GDA (0.41) | GAAL3MBTL1TDP1MAPTGDA | |
| SCHEMBL18021977 | 0.74 | L3MBTL1 (0.43) | L3MBTL1TDP1MAPTPOLBNPSR1 | |
| SCHEMBL23394686 | 0.73 | KDM4E (0.43) | GAAL3MBTL1TDP1MAPTDYRK1A | |
| SCHEMBL8024 | 0.72 | — | — | |
| SCHEMBL71570 | 0.72 | — | — | |
| SCHEMBL7435778 | 0.72 | GABRG2 (0.42) | GAAL3MBTL1TDP1MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7737284-B2 | Synthesis of temozolomide and analogs | SCHERING PLOUGH CORP. (US) | 2010-06-15 | — | — | US | disclosed |
| US-7737284-B2 | Synthesis of temozolomide and analogs | SCHERING PLOUGH CORP. (US) | 2010-06-15 | — | — | US | disclosed |
| US-7737284-B2 | Synthesis of temozolomide and analogs | SCHERING PLOUGH CORP. (US) | 2010-06-15 | — | — | US | disclosed |
| US-20090023919-A1 | SYNTHESIS OF TEMOZOLOMIDE AND ANALOGS | SCHERING CORPORATION | 2009-01-22 | — | — | US | disclosed |
| US-20090023919-A1 | SYNTHESIS OF TEMOZOLOMIDE AND ANALOGS | SCHERING CORPORATION | 2009-01-22 | — | — | US | disclosed |
| US-20090023919-A1 | SYNTHESIS OF TEMOZOLOMIDE AND ANALOGS | SCHERING CORPORATION | 2009-01-22 | — | — | US | disclosed |
| US-7446209-B2 | Diazotizing a blocked 5-amino-1H-imidazole-4-carboxamide; hydrolysis; antitumor agents | SCHERING CORPORATION (US) | 2008-11-04 | — | — | US | disclosed |
| US-7446209-B2 | Diazotizing a blocked 5-amino-1H-imidazole-4-carboxamide; hydrolysis; antitumor agents | SCHERING CORPORATION (US) | 2008-11-04 | — | — | US | disclosed |
| US-7446209-B2 | Diazotizing a blocked 5-amino-1H-imidazole-4-carboxamide; hydrolysis; antitumor agents | SCHERING CORPORATION (US) | 2008-11-04 | — | — | US | disclosed |
| US-20060229456-A1 | Synthesis of Temozolomide and analogs | SCHERING CORPORATION | 2006-10-12 | — | — | US | disclosed |
| US-7087751-B2 | Diazotizing 5-amino-1H-imidazole-4-carboxamide derivative having divalent protecting group on amide that is readily removable by hydrolysis or hydrogenolysis | SCHERING CORPORATION (US) | 2006-08-08 | — | — | US | disclosed |
| US-20050131227-A1 | Synthesis of temozolomide and analogs | SCHERING CORPORATION | 2005-06-16 | — | — | US | disclosed |
| EP-1353924-A1 | SYNTHESIS OF TEMOZOLOMIDE AND ANALOGS | Schering Corporation (US) | 2003-10-22 | — | — | EP | disclosed |
| WO-2002057269-A1 | SYNTHESIS OF TEMOZOLOMIDE AND ANALOGS | SCHERING CORPORATION (US) | 2002-07-25 | — | — | WO | disclosed |
| US-20020095036-A1 | Synthesis of temozolomide and analogs | SCHERING CORPORATION | 2002-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023919-A1 | SYNTHESIS OF TEMOZOLOMIDE AND ANALOGS | MGMT, TYMS, MCL1 | GAA 3301/4885L3MBTL1 2632/4885TDP1 144/4885 |
| US-20050131227-A1 | Synthesis of temozolomide and analogs | MGMT, TYMS, MCL1 | GAA 3301/4885L3MBTL1 2632/4885TDP1 144/4885 |
| US-20060229456-A1 | Synthesis of Temozolomide and analogs | MGMT, TYMS, MCL1 | GAA 3301/4885L3MBTL1 2632/4885TDP1 144/4885 |
| US-20020095036-A1 | Synthesis of temozolomide and analogs | MGMT, TYMS, MCL1 | GAA 3301/4885L3MBTL1 2632/4885TDP1 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.